Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5173881
Max Phase: Preclinical
Molecular Formula: C37H35N3O8S2
Molecular Weight: 713.83
Associated Items:
ID: ALA5173881
Max Phase: Preclinical
Molecular Formula: C37H35N3O8S2
Molecular Weight: 713.83
Associated Items:
Canonical SMILES: O=C(CCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21)Nc1cccc2c(OS(=O)(=O)C3CC4OC3C(c3ccc(O)cc3)=C4c3ccc(O)cc3)cccc12
Standard InChI: InChI=1S/C37H35N3O8S2/c41-22-14-10-20(11-15-22)33-29-18-31(36(47-29)34(33)21-12-16-23(42)17-13-21)50(45,46)48-28-7-2-4-24-25(28)5-1-6-26(24)38-32(43)9-3-8-30-35-27(19-49-30)39-37(44)40-35/h1-2,4-7,10-17,27,29-31,35-36,41-42H,3,8-9,18-19H2,(H,38,43)(H2,39,40,44)/t27-,29?,30-,31?,35-,36?/m0/s1
Standard InChI Key: YRUVMSBNJBCLNG-ZRNNMTHPSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 713.83 | Molecular Weight (Monoisotopic): 713.1866 | AlogP: 5.38 | #Rotatable Bonds: 10 |
Polar Surface Area: 163.29 | Molecular Species: NEUTRAL | HBA: 9 | HBD: 5 |
#RO5 Violations: 2 | HBA (Lipinski): 11 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 9.00 | CX Basic pKa: | CX LogP: 4.51 | CX LogD: 4.50 |
Aromatic Rings: 4 | Heavy Atoms: 50 | QED Weighted: 0.11 | Np Likeness Score: -0.22 |
1. Deng X, Xie B, Li Q, Xiao Y, Hu Z, Deng X, Fang P, Dong C, Zhou HB, Huang J.. (2022) Discovery of Novel Bicyclic Phenylselenyl-Containing Hybrids: An Orally Bioavailable, Potential, and Multiacting Class of Estrogen Receptor Modulators against Endocrine-Resistant Breast Cancer., 65 (11.0): [PMID:35611405] [10.1021/acs.jmedchem.2c00525] |
Source(1):